Eli Lilly and Company Archives

Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics

Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.

Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.

Find out how OliX Pharmaceuticals’ KRW 110 billion raise could reshape RNAi therapeutics, beauty biotech, and siRNA platform strategy.

Eli Lilly’s Haisco deal could be worth over $3 billion. Find out why China-originated drug discovery is becoming harder to ignore.

Read why Lilly’s Hanmi sonefpeglutide deal could reshape long-acting GLP-2 therapy for short bowel syndrome.

Find out how AAHI’s SLA-SE adjuvant could shape Lilly’s next-generation shingles vaccine strategy after the Curevo acquisition.

Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.

Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.

Eli Lilly’s Engage Bio deal is small by its standards, but DNA delivery may become a big battleground in genetic medicines.

RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.